Thyroid receptor ligands. 6. A high affinity "direct antagonist" selective for the thyroid hormone receptor

Journal of Medicinal Chemistry

Volumn 49, Issue 23, 2006, Pages 6635-6637

  Koehler, Konrad ^a   Gordon, Sandra ^a   Brandt, Peter ^a   Carlsson, Bo ^a   Bäcksbro Saeidi, Anna ^a   Apelqvist, Theresa ^a   Agback, Peter ^a   Grover, Gary J ^b   Nelson, William ^a   Grynfarb, Marlena ^a   Färnegårdh, Mathias ^a   Rehnmark, Stefan ^a   Malm, Johan ^a  

^a Karo Bio   (Sweden)

^b Eurofins Medinet Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3,5 DIBROMO 4 [4 HYDROXY 3 ISOPROPYL 5 (2 PYRIDIN 4 YLVINYL)PHENOXY]PHENYL]PROPIONIC ACID; ANTITHYROID AGENT; BENZENE DERIVATIVE; BROMINE DERIVATIVE; LIGAND; PROPIONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE; THYROID HORMONE RECEPTOR; THYROID HORMONE RECEPTOR ALPHA; THYROID HORMONE RECEPTOR ANTAGONIST; THYROID HORMONE RECEPTOR BETA; UNCLASSIFIED DRUG; VINYL DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BINDING SITE; DRUG CONFORMATION; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HYDROGEN BOND; IC 50; IN VIVO STUDY; LIGAND BINDING; NONHUMAN; QUANTUM YIELD; RAT; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; TRANSACTIVATION;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; LIGANDS; MODELS, MOLECULAR; PHENYLPROPIONATES; PYRIDINES; RATS; RECEPTORS, THYROID HORMONE; THYROID HORMONE RECEPTORS ALPHA; THYROID HORMONE RECEPTORS BETA; TRANS-ACTIVATION (GENETICS);

EID: 33750970574     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060521i     Document Type: Article

References (27)

1. Lazar, M. A. Thyroid hormone receptors: multiple forms, multiple possibilities. Endocr. Rev. 1993, 14, 184-193.
2. Wagner, R. L.: Apriletti, J. W.; McGrath, M. E.; West, B. L.; Baxter, J. D.; Fletterick, R. J. A structural role for hormone in the thyroid hormone receptor. Nature 1995, 378, 690-697.
3. Darimont, B. D.; Wagner, R. L.; Apriletti, J. W.; Stallcup, M. R.; Kushner, P. J.; Baxter, J. D.; Fletterick, R. J.; Yamamoto, K. R. Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev. 1998, 12, 3343-3356.
4. Wagner, R. L.; Huber, R. B.; Shiau, A. K.; Kelly, A.; Cunha Lima, S. T.; Scanlan, T. S.; Apriletti, J. W.; Baxter, J. D.; West, B. L.; Fletterick, R. J. Hormone selectivity in thyroid hormone receptors. Mol. Endocrinol. 2001, 15, 398-410.
5. Dow, R. L.; Schneller, S. R.; Paight, E. S.; Hank, R. F.; Chiang, P.; Cornelius, P.; Lee, E.; Newsome, W. P.; Swick, A. G.; Spitzer, J.; Hargrove, D. M.; Patterson, T. A.; Pandit, J.; Chrunyk, B. A.; LeMotte, P. K.; Danley, D. E.; Rosner, M. H.; Ammirati, M. J.; Simons, S. P.; Schulte, G. K.; Tate, B. F.; DaSilva-Jardine, P. Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TR beta subtype-selective thyromimetics. Bioorg. Med. Chem. Lett. 2003, 13, 379-382.
6. Ye, L.; Li, Y. L.; Mellström, K.; Mellin, C.; Bladh, L. G.; Koehler, K. F.; Garg, N.; Garcia Collazo, A. M.; Litten, C.; Husman, B.; Persson, K.; Ljunggren, J.; Grover, G.; Sleph, P. G.; George, R.; Malm, J. Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor betal. J. Med. Chem. 2003, 46, 1580-1588.
7. Hangeland, J. J.; Doweyko, A. M.; Dejneka, T.; Friends, T. J.; Devasthale, P.; Mellstrom, K.; Sandberg, J.; Grynfarb, M.; Sack, J. S.; Einspahr, H.; Färnegardh, M.; Husman, B.; Ljunggren, J.; Koehler, K.; Sheppard, C.; Malm, J.; Ryono, D. E. Thyroid receptor ligands. Part 2: Thyromimetics with improved selectivity for the thyroid hormone receptor beta. Bioorg. Med. Chem. Lett. 2004, 14, 3549-3553.
8. Sandler, B.; Webb, P.; Apriletti, J. W.; Huber, R. R.; Togashi, M.; Cunha Lima, S. T.; Juric, S.; Nilsson, S.; Wagner, R.; Fletterick, R. J.; Baxter, J. D. Thyroxine-thyroid hormone receptor interactions. J. Biol. Chem. 2004, 279, 55801-55808.
9. Borngraeber, S.; Budny, M. J.; Chiellini, G.; Cunha-Lima, S. T.; Togashi, M.; Webb, P.; Baxter, J. D.; Scanlan, T. S.; Fletterick, R. J. Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 15358-15363.
10. The distinction between "direct", "indirect", and "passive" antagonists has been outlined in the following. Hedfors. Å.; Appelqvist, T.; Carlsson, B.; Bladh, L.-B.; Litten, C.; Agback, P.; Grynfarb, M.; Koehler, K. F.; Malm, J. Thyroid receptor ligands. 3. Design and synthesis of 3,5-dihalo-4-alkoxyphenylalkanoic acids as indirect antagonists of the thyroid hormone receptor. J. Med. Chem, 2005, 48, 3114-3117.
11. Reid, D. G.; Maclachlan, L. K.; Voyle, M.; Leeson, P. D. A proton and fluorine-19 nuclear magnetic resonance and fluorescence study of the binding of some natural and synthetic thyromimetics to prealbumin (transthyretin). J. Biol. Chem. 1989, 264, 2013-2023.
12. Shulkin, B. L.; Bolger, M. B.; Utiger, R. D. Thyroid hormone analog inhibition of hepatic 5′-iodothyronine deiodinase activity. J. Endocrinol. Invest. 1988, 11, 657-661.
13. Koehrle, J.; Auf'mkolk, M.; Rokos, H.; Hesch, R. D.; Cody, V. Rat liver iodothyronine monodeiodinase. Evaluation of the iodothyronine ligand-binding site. J. Biol. Chem. 1986, 261, 11613-11622.
14. Tropsha, A. E.; Rakhmaninova, A. B.; laguzhinskii, L. S. Configration and properties of a binding site for thyroid hormones on a specific receptor. Bioorg. Khim. 1984, 10, 483-492.
15. Bolger, M. B.; Jorgensen, E. C. Molecular interactions between thyroid hormone analogs and the rat liver nuclear receptor. Partitioning of equilibrium binding free energy changes into substituent group interactions. J. Biol. Chem. 1980, 255, 10271-10278.
16. Dietrich, S. W.; Bolger, M. B.; Kollman, P. A.; Jorgensen, E. C. Thyroxine analogues. 23. Quantitative structure-activity correlation studies of in vivo and in vitro thyromimetic activities. J. Med. Chem. 1977, 20, 863-880.
17. Koerner, D.; Schwartz, H. L.; Surks, M. L.; Oppenheimer, J. H. Binding of selected iodothyronine analogues to receptor sites of isolated rat hepatic nuclei. High correlation between structural requirements for nuclear binding and biological activity. J. Biol. Chem. 1975, 250, 6417-6423.
18. Baxter, J. D.; Goede, P.; Apriletti, J. W.; West, B. L.; Feng, W.; Mellström, K.; Fletterick, R. J.; Wagner, R. L.; Kushner, P. J.; Ribeiro, R. C. J.; Webb, P.; Scanlan, T. S.; Nilsson, S. Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist. Endocrinology 2002, 143, 517-524.
19. Chiellini, G.; Nguyen, N. H.; Apriletti, J. W.; Baxter, J. D.; Scanlan, T. S. Synthesis and biological activity of novel thyroid hormone analogues: 5′-aryl substituted GC-1 derivatives. Bioorg. Med. Chem. Lett. 2002, 10, 333-346.
20. Nguyen, N. H.; Apriletti, J. W.; Lima, S. T. C.; Webb, P.; Baxter, J. D.; Scanlan, T. S. Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment. J. Med. Chem. 2002, 45, 3310-3320.
21. Lim, W.; Nguyen, N. H.; Yang, H. Y.; Scanlan, T. S.; Furlow, J. D. A thyroid hormone antagonist that inhibits thyroid hormone action in vivo. J. Biol. Chem. 2002, 277, 35664-35670.
22. Bates, W. B.; Gabel, C. J.; Ji, J.; Rama-Devi, T. Synthesis of phenolic natural products using palladium catalyzed coupling reactions. Tetrahedron 1995, 51, 8199-8212.
23. Since there are no available crystallographic structures of antagonists bound to TR, a partial homology model of the LBD of TR/3 in the antagonist conformation was constructed using the crystallographic structure of hTRβ/3-[3,5-dibromo-4-(3-isopropyl-4-methoxyphenoxy)phenyl]propionate (7), (in which H12 adopts the canonical agonist conformation; PDB accession code 2j4a) and hRAR-α/BMS-614 (where H12 in an antagonist orientation; PDB accession code IDKF). The experimental procedure can be found in the Supporting Information.
24. Yokoyama, N.; Walker, G. N.; Main, A. J.; Stanton, J. L.; Morrissey, M. M.; Boehm, C.; Engle, A.; Neubert, A. D.; Wasvary, J. M.; Stephan, Z. F.; Steele, R. E. Synthesis and structure-activity relationships of oxamic acid and acetic acid derivatives related to L-thyronine. J. Med. Chem. 1995, 38, 695-707.
25. DeLano, W. L. The PyMOL Molecular Graphics System; DeLano Scientific: San Carlos, CA, 2002; http://www.pymol.org.
26. Carlsson, B.; Singh, B. N.; Temciuc, M.; Nilsson, S.; Li, Y. L.; Mellin, C.; Malm, J. Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB 130015) with an improved toxicity profile compared with amiodarone. J. Med. Chem. 2002, 45, 623-630.
27. Grover, J. G.; Mellström, K.; Ye, L.; Malm, J.; Li, Y.-L.; Bladh, L.-G.; Sleph, P. G.; Smith, M. A.; George, R.; Vennström, B.; Mookhtiar, K.; Horvath, R.; Speelman, J.; Egan, D.; Baxter, J. D. Selective thyroid hormone receptor-β activation; a strategy for reduction of weight, cholesterol, and Lp(a) with reduced cardiovascular liability. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 10067-10072.